Preexposure prophylaxis for preventing HIV infection: Routine practice in primary care.
Cleve Clin J Med
; 91(6): 361-371, 2024 Jun 03.
Article
in En
| MEDLINE
| ID: mdl-38830701
ABSTRACT
An estimated 1.2 million people in the United States have human immunodeficiency virus (HIV) infection per US Centers for Disease Control and Prevention 2021 data. The highest risk of HIV transmission occurs during injection drug use with needle sharing and during sexual activity, most significantly in condomless, receptive anal intercourse. Preexposure prophylaxis (PrEP) for the prevention of HIV infection is part of a larger biobehavioral strategy that uses antiretroviral medication, an oral formulation taken daily or during anticipated exposure events, or an injectable formulation administered every 8 weeks. PrEP consists of 3 possible regimens emtricitabine/tenofovir disoproxil fumarate, emtricitabine/tenofovir alafenamide, or injectable cabotegravir. Primary care clinicians are strategically positioned to provide PrEP education and access.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Primary Health Care
/
HIV Infections
/
Pre-Exposure Prophylaxis
Limits:
Humans
/
Male
Language:
En
Journal:
Cleve Clin J Med
/
Clevel. clin. j. med
/
Cleveland clinic journal of medicine
Journal subject:
MEDICINA
Year:
2024
Document type:
Article
Country of publication: